Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open-label study to investigate the safety, tolerability, and exposure of single ascending doses of the antisense oligonucleotide STK-002 in patients with autosomal dominant optic atrophy

Next Previous
Trial Profile

An open-label study to investigate the safety, tolerability, and exposure of single ascending doses of the antisense oligonucleotide STK-002 in patients with autosomal dominant optic atrophy

Status: Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs STK 002 (Primary)
  • Indications Optic atrophy
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms OSPREY
  • Sponsors Stoke Therapeutics

Most Recent Events

  • 05 Nov 2024 According to Stoke Therapeutics media release, as company continues to focus on zorevunersen as its lead program, it will delay the start of the Phase 1 study of STK-002, its clinical candidate for the treatment of autosomal dominant optic atrophy (ADOA).
  • 11 Mar 2024 Planned End Date changed from 8 Dec 2026 to 31 Mar 2029.
  • 11 Mar 2024 The recruitment completion date is 31 Aug 2028,according to ISRCTN: Current Controlled Trials record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top